Nanocarrier-Mediated Chemotherapy for Oral Squamous Cell Carcinoma: Pharmacokinetics, Tumor Targeting, and Safety
DOI:
https://doi.org/10.22159/ajpcr.2026v19i3.57660Keywords:
Nanocarriers, Chemotherapy, Pharmacokinetics, Tumor-targeting, Safety,, OSCC.Abstract
Oral squamous cell carcinoma often fails chemotherapy because effective intratumoral exposure cannot be sustained without unacceptable systemic toxicity, a mismatch amplified by salivary washout and mucosal barriers in the oral cavity. This narrative review reframes nanocarrier chemotherapy as exposure engineering, defined here as the deliberate design of delivery systems to control the spatial and temporal distribution of drug concentrations across clinically relevant compartments (tumor, regional lymph nodes, and blood), and integrates three co-primary domains: Pharmacokinetics, tumor-targeting with intratumoral coverage, and route-matched safety-by-design. This review emphasizes defining success by compartment-level exposure outcomes, especially tumor and regional lymph-node delivery with minimal systemic peaks, using a transmucosal cisplatin patch paradigm as a translational benchmark. The review also shifts evaluation from accumulation to coverage by prioritizing spatial uniformity metrics that capture underdosed niches. Finally, it extends safety requirements to externally triggered platforms through modality-specific dosimetry and collateral injury surveillance, and proposes a standardization checklist to improve reproducibility and human-forward translation.
Downloads
References
1. De Morais EF, De Oliveira LQ, Marques CE, Morais HG, Moreira DG, De Albuquerque LA, et al. Molecular mechanisms of chemoresistance in oral squamous cell carcinoma: A narrative review with present and future perspectives. Appl Sci. 2026;16(1):525. doi: 10.3390/ app16010525
2. Mahmoudi Anzabi R, Davodpour AH, Ghodratizadeh S, Nikeghbal D, Sadeghzade A, Mohammadikhah M, et al. Recent knowledge on squamous cell carcinoma of the oral cavity: Contributing factors, underlying molecular pathways, and current attitudes in the therapeutic approaches. Int J Mol Cell Med. 2025;14(3):928-48. doi: 10.22088/IJMCM.BUMS.14.3.928, PMID 41321969, PMCID PMC12664692
3. Imbesi Bellantoni M, Picciolo G, Pirrotta I, Irrera N, Vaccaro M, Vaccaro F, et al. Oral cavity squamous cell carcinoma: An update of the pharmacological treatment. Biomedicines. 2023;11(4):1112. doi: 10.3390/biomedicines11041112, PMID 37189730
4. Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, et al. Oral squamous cell carcinomas: State of the field and emerging directions. Int J Oral Sci. 2023;15(1):44. doi: 10.1038/s41368-023-00249-w, PMID 37736748, PMCID PMC10517027
5. Shebbo S, Alateyah N, Yassin E, Mahmoud DE, Tamimi F, Anweigi L, et al. Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: An insight into disease complexity, available therapies, and future considerations. Front Immunol. 2025;16:1626243. doi: 10.3389/fimmu.2025.1626243, PMID 40881676, PMCID PMC12380768
6. Zhang H, Zhou F, Yang Q, Huang M. Targeting the oral tumor microenvironment by nanoparticles: A review of progresses. J Drug Deliv Sci Technol. 2024;91:105248. doi: 10.1016/j.jddst.2023.105248
7. Zeinali R, Zaeifi D, Zolfaghari-Moghaddam SY, Paul MK, Biazar E. Current advances in nanocarriers for cancer therapy. Int J Nanomedicine. 2025;20:12217-62. doi: 10.2147/IJN.S548088, PMID 41078404
8. Pandey M, Choudhury H, Ying JN, Ling JF, Ting J, Ting JS, et al. Mucoadhesive nanocarriers as a promising strategy to enhance intracellular delivery against oral cavity carcinoma. Pharmaceutics. 2022;14(4):795. doi: 10.3390/pharmaceutics14040795, PMID 35456629
9. Herrada Céspedes A, Reyes M, Morales JO. Advanced drug delivery systems for oral squamous cell carcinoma: A comprehensive review of nanotechnology-based and other innovative approaches. Front Drug Deliv. 2025;5:1596964. doi: 10.3389/fddev.2025.1596964, PMID 40837711
10. Goldberg M, Manzi A, Birdi A, Laporte B, Conway P, Cantin S, et al. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022;13(1):4829. doi: 10.1038/s41467-022- 31859-3, PMID 35977936
11. Bardhan D, Parmar D, Srivastava AP, Sanda S, Panda JP, Shetty UA, et al. Photodynamic therapy versus surgery in management of oral squamous cell carcinoma: A comparative study. J Pharm Bioallied Sci. 2025;17 Suppl 3:S2416-8. doi: 10.4103/jpbs.jpbs_1851_24, PMID 41164586, PMCID PMC12564073
12. Menditti D, Santagata M, Imola G, Staglianò S, Vitagliano R, Boschetti CE, et al. Personalized medicine in oral oncology: Imaging methods and biological markers to support diagnosis of oral squamous cell carcinoma (OSCC): A narrative literature review. J Pers Med. 2023;13(9):1397. doi: 10.3390/jpm13091397, PMID 37763165
13. Kazemi KS, Kazemi P, Mivehchi H, Nasiri K, Eshagh Hoseini SS, Nejati ST, et al. Photodynamic therapy: A novel approach for head and neck cancer treatment with focusing on oral cavity. Biol Proced Online. 2024;26(1):25. doi: 10.1186/s12575-024-00252-3, PMID 39154015, PMCID PMC11330087
14. Ebrahimi H, Sharifzadeh S, Meftahpour H. Role of photodynamic therapy in the treatment of oral cancer: A review. J Res Dent Maxillofac Sci. 2021;6:29-35.
15. Esperouz F, Lorusso M, Santarelli A, De Lillo A, Lo Muzio L, Ciavarella D, et al. Photodynamic therapy and nanomedicine: Current knowledge, limitations, and applications in oral squamous cell carcinoma: A narrative review. Front Oncol. 2025;15:1619560. doi: 10.3389/fonc.2025.1619560, PMID 40589639, PMCID PMC12206862
16. Saini R, Lee NV, Liu KY, Poh CF. Prospects in the application of photodynamic therapy in oral cancer and premalignant lesions. Cancers (Basel). 2016;8(9):83. doi: 10.3390/cancers8090083, PMID 27598202
17. Saberi S, Hakimiha N, Alaeddini M, Etemad-Moghadam S, Roudbari P, Shahabi S. In vitro anti-tumor effects of photodynamic therapy on oral squamous cell carcinoma: A review. J Lasers Med Sci. 2022;13:e49. doi: 10.34172/jlms.2022.49, PMID 37041780, PMCID PMC10082907
18. Cardoso M, Marto CM, Paula A, Coelho AS, Amaro I, Pineiro M, et al. Effectiveness of photodynamic therapy on treatment response and survival in patients with recurrent oral squamous cell carcinoma: A systematic review. Photodiagn Photodyn Ther. 2024;48:104242. doi: 10.1016/j.pdpdt.2024.104242, PMID 38857775
19. Bharadwaj R, Sahu BP, Haloi J, Laloo D, Barooah P, Keppen C, et al. Combinatorial therapeutic approach for treatment of oral squamous cell carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):572-85. doi: 10.1080/21691401.2019.1573176, PMID 30831033
20. Zhou Y, Wang L, Liu M, Jiang H, Wu Y. Oral squamous cell carcinoma: Insights into cellular heterogeneity, drug resistance, and evolutionary trajectories. Cell Biol Toxicol. 2025;41(1):101. doi: 10.1007/s10565- 025-10048-0, PMID 40504271, PMCID PMC12162747
21. Jawa Y, Yadav P, Gupta S, Mathan SV, Pandey J, Saxena AK, et al. Current insights and advancements in head and neck cancer: Emerging biomarkers and therapeutics with cues from single cell and 3D model omics profiling. Front Oncol. 2021;11:676948. doi: 10.3389/ fonc.2021.676948, PMID 34490084
22. Sadeghzade A, Jafarian A, Davodpour AH, Pouresmaeliyan Roumani M, Mohammadikhah M, Qutaiba Badraldeen S, et al. Oral squamous cell carcinoma pharmacological treatment; A long non-coding RNAs (long ncRNAs) story. Int J Mol Cell Med. 2025;14(2):736-52. doi: 10.22088/IJMCM.BUMS.14.2.736, PMID 40765751, PMCID PMC12321307
23. Zhang W, Chen S, Bai Z, Gan M, Chen M, Zhang Y, et al. Photodynamic therapy for oral squamous cell carcinoma: Current status, challenges, and prospects. Int J Nanomedicine. 2024;19:10699-710. doi: 10.2147/ IJN.S481901, PMID 39464676
24. Chen X, Kuang S, He Y, Li H, Yi C, Li Y, et al. The differential metabolic response of oral squamous cell carcinoma cells and normal oral epithelial cells to cisplatin exposure. Metabolites. 2022;12(5):389. doi: 10.3390/ metabo12050389, PMID 35629893, PMCID PMC9147301
25. Ketabat F, Pundir M, Mohabatpour F, Lobanova L, Koutsopoulos S, Hadjiiski L, et al. Controlled drug delivery systems for oral cancer treatment-current status and future perspectives. Pharmaceutics. 2019;11(7):302. doi: 10.3390/pharmaceutics11070302, PMID 31262096
26. De Felice F, Cavallini C, Barlattani A, Tombolini M, Brugnoletti O, Tombolini V, et al. Nanotechnology in oral cavity carcinoma: Recent trends and treatment opportunities. Nanomaterials (Basel). 2019;9(11):1546. doi: 10.3390/nano9111546, PMID 31683582
27. Feng Z, Hao P, Yang Y, Xve X, Zhang J. Network pharmacologyand molecular docking to explore the potential molecular mechanism of chlorogenic acid treatment of oral squamous cell carcinoma. Med (Baltimore). 2024;103(45):e40218. doi: 10.1097/ MD.0000000000040218, PMID 39533555, PMCID PMC11557041
28. Schreder K, Wickenhauser C, Kappler M, Tavassol F, Eckert AW. Metabolic biomarker in oral squamous cell carcinoma -a comprehensive review. GMS Interdiscip Plast Reconstr Surg DGPW. 2025;14:Doc01. doi: 10.3205/iprs000190, PMID 40535577, PMCID PMC12171862
29. Girigoswami K, Pallavi P, Girigoswami A. Intricate subcellular journey of nanoparticles to the enigmatic domains of endoplasmic reticulum. Drug Deliv. 2023;30(1):2284684. doi: 10.1080/10717544.2023.2284684, PMID 37990530, PMCID PMC10987057
30. Ju S, Chen C, Zhang J, Xu L, Zhang X, Li Z, et al. Detection of circulating tumor cells: Opportunities and challenges. Biomark Res. 2022;10(1):58. doi: 10.1186/s40364-022-00403-2, PMID 35962400
31. Proietto M, Crippa M, Damiani C, Pasquale V, Sacco E, Vanoni M, et al. Tumor heterogeneity: Preclinical models, emerging technologies, and future applications. Front Oncol. 2023;13:1164535. doi: 10.3389/ fonc.2023.1164535, PMID 37188201
32. Irannejadrankouhi S, Mivehchi H, Eskandari-Yaghbastlo A, Nejati ST, Emrahoglu S, Nazarian M, et al. Innovative nanoparticle strategies for treating oral cancers. Med Oncol. 2025;42(6):182. doi: 10.1007/ s12032-025-02728-y, PMID 40285805
33. Chaudhary AA, Fareed M, Khan SU, Alneghery LM, Aslam M, Alex A, et al. Exploring the therapeutic potential of lipid-based nanoparticles in the management of oral squamous cell carcinoma. Explor Target Antitumor Ther. 2024;5(6):1223-46. doi: 10.37349/etat.2024.00272, PMID 39465011
34. Zhu X, Chen J, Zhao J, Zhang Z, Wang C. Nanomaterials for theranostic management of oral cancer: Advances in imaging, biosensing, targeted delivery, and multimodal synergistic therapy. Int J Nanomedicine. 2025;20:13689-719. doi: 10.2147/IJN.S560993, PMID 41255464, PMCID PMC12621618
35. Kesharwani P, Kumar V, Goh KW, Gupta G, Alsayari A, Wahab S, et al. Pegylated PLGA nanoparticles: Unlocking advanced strategies for cancer therapy. Mol Cancer. 2025;24(1):205. doi: 10.1186/s12943- 025-02410-x, PMID 40702523, PMCID PMC12288292
36. Yang L, Li H, Luo A, Zhang Y, Chen H, Zhu L, et al. Macrophage membrane-camouflaged pH-sensitive nanoparticles for targeted therapy of oral squamous cell carcinoma. J Nanobiotechnology. 2024;22(1):168. doi: 10.1186/s12951-024-02433-4, PMID 38610015
37. Li R, Wan C, Li Y, Jiao X, Liu T, Gu Y, et al. Nanocarrier-based drug delivery system with dual targeting and NIR/pH response for synergistic treatment of oral squamous cell carcinoma. Colloids Surf B Biointerfaces. 2024;244:114179. doi: 10.1016/j.colsurfb.2024.114179, PMID 39217727
38. Caponio VC, Zhurakivska K, Lo Muzio L, Troiano G, Cirillo N. The immune cells in the development of oral squamous cell carcinoma. Cancers (Basel). 2023;15(15):3779. doi: 10.3390/cancers15153779, PMID 37568595, PMCID PMC10417065
39. Venkatesiah SS, Augustine D, Mishra D, Gujjar N, Haragannavar VC, Awan KH, et al. Immunology of oral squamous cell carcinoma-a comprehensive insight with recent concepts. Life (Basel). 2022;12(11):1807. doi: 10.3390/life12111807, PMID 36362963, PMCID PMC9695443
40. Tang B, Huang R, Ma W. Advances in nanotechnology-based approaches for the treatment of head and neck squamous cell carcinoma. RSC Adv. 2024;14(52):38668-88. doi: 10.1039/D4RA07193J, PMID 39654926
41. Fan HY, Zhao MD, Jiang HJ, Yu ZW, Fan YJ, Liang XH et al. Cisplatin-based miRNA delivery strategy inspired by the circCPNE1/ miR-330-3p pathway for oral squamous cell carcinoma. Acta Pharm Sin B. 2024;14(6):2748-60. doi: 10.1016/j.apsb.2024.02.009, PMID 38828155, PMCID PMC11143742
42. Hussein NI, Molina AH, Sunga GM, Amit M, Lei YL, Zhao X, et al. Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders. Oral Oncol. 2024;158:106986. doi: 10.1016/j.oraloncology.2024.106986, PMID 39137489, PMCID PMC11879773
43. Suri S, Boora GS, Kaur R, Chauhan A, Ghoshal S, Pal A. Recent advances in minimally invasive biomarkers of OSCC: From generalized to personalized approach. Front Oral Health. 2024;5:1426507. doi: 10.3389/ froh.2024.1426507, PMID 39157206, PMCID PMC11327221
44. Kim H, Lee SM, Ahn KM. The epidemiological and histopathological factors for delayed local recurrence in oral squamous cell carcinoma. Maxillofac Plast Reconstr Surg. 2024;46(1):38. doi: 10.1186/s40902- 024-00443-8, PMID 39531141, PMCID PMC11557773
45. Valero C, Zanoni DK, Pillai A, Xu B, Katabi N, Ghossein RA, et al. Nodal characteristics associated with adverse prognosis in oral cavity cancer are linked to host immune status. J Surg Oncol. 2021;123(1):141-8. doi: 10.1002/jso.26235, PMID 32974936, PMCID PMC7770005
46. Li R, Liu C, Wan C, Liu T, Zhang R, Du J, et al. A targeted and pH-responsive nano-graphene oxide nanoparticle loaded with doxorubicin for synergetic chemo-photothermal therapy of oral squamous cell carcinoma. Int J Nanomedicine. 2023;18:3309-24. doi: 10.2147/IJN. S402249, PMID 37351329
47. Spada A, Gerber-Lemaire S. Surface functionalization of nanocarriers with anti-EGFR ligands for cancer active targeting. Nanomaterials (Basel). 2025;15(3):158. doi: 10.3390/nano15030158, PMID 39940134
48. Abdel Hamid HM, Darwish ZE, Elsheikh SM, Mourad GM, Donia HM, Afifi MM. Following cytotoxic nanoconjugates from injection to halting the cell cycle machinery and its therapeutic implications in oral cancer. BMC Cancer. 2021;21(1):170. doi: 10.1186/s12885-021- 07849-x, PMID 33596850
49. Wu J. The enhanced permeability and retention (EPR) effect: The significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771. doi: 10.3390/jpm11080771, PMID 34442415, PMCID PMC8402171
50. Vagena IA, Malapani C, Gatou MA, Lagopati N, Pavlatou EA. Enhancement of EPR effect for passive tumor targeting: Current status and future perspectives. Appl Sci. 2025;15(6):3189. doi: 10.3390/ app15063189
51. Elemike EE, Onunkwo IC, Ughumiakpor O, Alawuru F, Mukoro A, Ishom P, et al. Bio-nanomaterials: Promising anticancer properties and treatment strategies. Nano TransMed. 2025;4:100076. doi: 10.1016/j. ntm.2025.100076
52. Bazak R, Houri M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol Clin Oncol. 2014;2(6):904-8. doi: 10.3892/mco.2014.356, PMID 25279172, PMCID PMC4179822
53. Chiodelli P, Papait A, Agoni L, Quaglia F, Silini AR, Parolini O. The tumor ecosystem: Rewiring an open, systemically integrated network for therapeutic gain. Biomed Pharmacother. 2026;195:119047. doi: 10.1016/j.biopha.2026.119047, PMID 41592526
54. Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17-38. doi: 10.1016/j.addr.2018.07.007, PMID 30009886, PMCID PMC6130746
55. Mitea G, Schröder V, Iancu IM. Bioactive plant-derived compounds as novel perspectives in oral cancer alternative therapy. Pharmaceuticals (Basel). 2025;18(8):1098. doi: 10.3390/ph18081098, PMID 40872490
56. Shang Q, Jiang Y, Wan Z, Peng J, Xu Z, Li W, et al. The clinical implication and translational research of OSCC differentiation. Br J Cancer. 2024;130(4):660-70. doi: 10.1038/s41416-023-02566-7, PMID 38177661, PMCID PMC10876927
57. Qu X, Li JW, Chan J, Meehan K. Extracellular vesicles in head and neck cancer: A potential new trend in diagnosis, prognosis, and treatment. Int J Mol Sci. 2020;21(21):8260. doi: 10.3390/ijms21218260, PMID 33158181
58. Cao M, Shi E, Wang H, Mao L, Wu Q, Li X, et al. Personalized targeted therapeutic strategies against oral squamous cell carcinoma. An evidence-based review of literature. Int J Nanomedicine. 2022;17:4293-306. doi: 10.2147/IJN.S377816, PMID 36134201
59. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2-25. doi: 10.1016/j. addr.2013.11.009, PMID 24270007, PMCID PMC4219254
60. Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review. Int J Nanomedicine. 2018;13:3921-35. doi: 10.2147/IJN. S165210, PMID 30013345, PMCID PMC6038858
61. Xu J, Chen H, Tao Y, Wang H, Wang Z, Xue Y, et al. A dual-target recognition system based on acid-degradable Ni‐MOF and aptamer guidance for precise tumor diagnosis and combined therapy. Adv Sci (Weinh). 2025;12(42):e12838. doi: 10.1002/advs.202512838, PMID 40990536, PMCID PMC12622455
62. Rehorst P, Kros A. A general logic-gating framework for CAR-T and nanocarrier cancer therapies: A cross-platform comparative analysis of logic architectures and their molecular implementation strategies. J Control Release. 2025;391:114583. doi: 10.1016/j. jconrel.2025.114583, PMID 41478377
63. Taghipour YD, Zarebkohan A, Salehi R, Rahimi F, Torchilin VP, Hamblin MR, et al. An update on dual targeting strategy for cancer treatment. J Control Release. 2022;349:67-96. doi: 10.1016/j. jconrel.2022.06.044, PMID 35779656
64. Mengyuan H, Aixue L, Yongwei G, Qingqing C, Huanhuan C, Xiaoyan L, et al. Biomimetic nanocarriers in cancer therapy: Based on intercellular and cell-tumor microenvironment communication. J Nanobiotechnology. 2024;22(1):604. doi: 10.1186/s12951-024- 02835-4, PMID 39370518
65. Feng J, He D, Chen J, Li M, Luo J, Han Y, et al. Cell membrane biomimetic nanoplatforms: A new strategy for immune escape and precision targeted therapy. Mater Today Bio. 2025;35:102343. doi: 10.1016/j.mtbio.2025.102343, PMID 41069689, PMCID PMC12506577
66. Rampado R, Caliceti P, Agostini M. Latest advances in biomimetic cell membrane-coated and membrane-derived nanovectors for biomedical applications. Nanomaterials (Basel). 2022;12(9):1543. doi: 10.3390/ nano12091543, PMID 35564251
67. Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006;116(7):1955-62. doi: 10.1172/JCI26532, PMID 16794736, PMCID PMC1481657
68. Kashyap BK, Singh VV, Solanki MK, Kumar A, Ruokolainen J, Kesari KK. Smart nanomaterials in cancer theranostics: Challenges and opportunities. ACS Omega. 2023;8(16):14290-320. doi: 10.1021/ acsomega.2c07840, PMID 37125102
69. Kang X, Chen K, Li Y, Li J, D’Amico TA, Chen X. Personalized targeted therapy for esophageal squamous cell carcinoma. World J Gastroenterol. 2015;21(25):7648-58. doi: 10.3748/wjg.v21.i25.7648, PMID 26167067
70. Lawaetz M, Christensen A, Juhl K, Karnov K, Lelkaitis G, Kanstrup Fiehn AM, et al. Potential of uPAR, αvβ6 integrin, and tissue factor as targets for molecular imaging of oral squamous cell carcinoma: Evaluation of nine targets in primary tumors and metastases by immunohistochemistry. Int J Mol Sci. 2023;24(4):3853. doi: 10.3390/ ijms24043853, PMID 36835265
71. Mohanapure NS, Khandeparkar SG, Saragade PB, Gogate BP, Joshi AR, Mehta SR. Immunohistochemical study of epidermal growth factor receptor, human epidermal growth factor receptor 2/ neu, p53, and Ki67 in oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2022;26(1):127-8. doi: 10.4103/jomfp.jomfp_310_21, PMID 35571320, PMCID PMC9106230
72. Sajjanar M, Sajjan P, Puranik RS, Vanaki S, Jayanth V, Naik P. “Analysis of immunohistochemical expression of epidermal growth factor receptor in oral squamous cell carcinoma using tissue microarray technology and whole sections:” A comparative study. J Oral Maxillofac Pathol. 2020;24(3):499-504. doi: 10.4103/jomfp.JOMFP_154_19, PMID 33967487, PMCID PMC8083405
73. Si Q, Wang Y, Lu W, Liu Z, Song Y, Chen S, et al. Transferrin receptor uptakes iron from tumor-associated neutrophils to regulate invasion patterns of OSCC. Cancer Immunol Immunother. 2025;74(2):43. doi: 10.1007/s00262-024-03894-0, PMID 39751915, PMCID PMC11699170
74. Olguins DB, Marcolin JC, Da Cunha Jaeger M, Martins MD, Da Rosa Rivero LF, Schwartsmann G, et al. The gastrin-releasing peptide receptor as a potential biomarker for squamous cell carcinoma. Sci Rep. 2025;15(1):41061. doi: 10.1038/s41598-025-24861-4, PMID 41266536
75. Aamir R, Rauf F, Iqbal F, Yousuf S, Rehman A, Sheikh AK, et al. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma and oral potentially malignant disorders. Appl Immunohistochem Mol Morphol. 2024;32(3):157-62. doi: 10.1097/PAI.0000000000001185, PMID 38268382
76. Singh M, Agrawal P, Sharma E, Yadav JS, Sethi C, Sharma N. Expression of CD44 and its correlation with clinicopathological factors in oral and oropharyngeal carcinoma: A retrospective immunohistochemical study. Cureus. 2025;17(3):e81274. doi: 10.7759/cureus.81274, PMID 40291275, PMCID PMC12032826
77. Monteiro LS, Delgado ML, Ricardo S, Do Amaral B, Salazar F, Pacheco JJ, et al. Prognostic significance of CD44v6, p63, podoplanin and MMP-9 in oral squamous cell carcinomas. Oral Dis. 2016;22(4):303-12. doi: 10.1111/odi.12442, PMID 26788715
78. Mulder FJ, De Ruiter EJ, Gielgens T, Farshadpour F, De Bree R, Van Den Hout M, et al. Frequent PD-L1 expression in oral squamous cell carcinoma of non-smokers and non-drinkers, and association of tumor infiltrating lymphocytes with favorable prognosis. Transl Oncol. 2025;55:102357. doi: 10.1016/j.tranon.2025.102357, PMID 40090069, PMCID PMC11957585
79. He X, Chen S, Tang Y, Zhao X, Yan L, Wu L, et al. Hepatocyte growth factor overexpression slows the progression of 4NQO-induced oral tumorigenesis. Front Oncol. 2021;11:756479. doi: 10.3389/ fonc.2021.756479, PMID 34970484, PMCID PMC8712676
80. Freudlsperger C, Alexander D, Reinert S, Hoffmann J. Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med. 2010;1(1):69-72. doi: 10.3892/etm_00000012, PMID 23136595, PMCID PMC3490346
81. Deepa AG, Janardanan-Nair B, Varun BR. Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma. J Clin Exp Dent. 2017;9(12):e1418-24. doi: 10.4317/jced.54213, PMID 29410757, PMCID PMC5794119
82. Aquino G, Sabatino R, Cantile M, Aversa C, Ionna F, Botti G, et al. Expression analysis of SPARC/osteonectin in oral squamous cell carcinoma patients: From saliva to surgical specimen. BioMed Res Int. 2013;2013:736438. doi: 10.1155/2013/736438, PMID 24396828, PMCID PMC3876772
83. Li R, Gao R, Wang Y, Liu Z, Xu H, Duan A, et al. Gastrin releasing peptide receptor targeted nano-graphene oxide for near-infrared fluorescence imaging of oral squamous cell carcinoma. Sci Rep. 2020;10(1):11434. doi: 10.1038/s41598-020-68203-y, PMID 32651409.
84. Wang Y, Wan G, Li Z, Shi S, Chen B, Li C, et al. Pegylated doxorubicin nanoparticles mediated by HN-1 peptide for targeted treatment of oral squamous cell carcinoma. Int J Pharm. 2017;525(1):21-31. doi: 10.1016/j.ijpharm.2017.04.027, PMID 28412450
85. Hassibian S, Amin M, Taghdisi SM, Sameiyan E, Ghaffari R, Alibolandi M, et al. Aptamers: Design, theory, and applications to diagnosis and therapy for diseases. MedComm (2020). 2025;6(5):e70180. doi: 10.1002/mco2.70180, PMID 40391083, PMCID PMC12086380
86. Zhou J, Rossi J. Aptamers as targeted therapeutics: Current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181-202. doi: 10.1038/ nrd.2016.199, PMID 27807347, PMCID PMC5700751
87. Vasilescu A, Gáspár S, Gheorghiu M, Polonschii C, Banciu RM, David S, et al. Promising solutions to address the non-specific adsorption in biosensors based on coupled electrochemical-surface plasmon resonance detection. Chemosensors. 2025;13(3):92. doi: 10.3390/chemosensors13030092
88. Kattimani V, Bhukya NK, Panga GS, Chakrabarty A, Lingamaneni P. Nano-drug carriers for targeted therapeutic approaches in oral cancer: A systematic review. J Maxillofac Oral Surg. 2024;23(4):763-71. doi: 10.1007/s12663-024-02251-z, PMID 39118900
89. Ma X, Yang R, Li H, Zhang X, Zhang X, Li X. Role of exosomes in the communication and treatment between OSCC and normal cells. Heliyon. 2024;10(7):e28148. doi: 10.1016/j.heliyon.2024.e28148, PMID 38560136
90. Desai N, Rana D, Pande S, Salave S, Giri J, Benival D, et al. “Bioinspired” membrane-coated nanosystems in cancer theranostics: A comprehensive review. Pharmaceutics. 2023;15(6):1677. doi: 10.3390/pharmaceutics15061677, PMID 37376125
91. Jin J, Bhujwalla ZM. Biomimetic nanoparticles camouflaged in cancer cell membranes and their applications in cancer theranostics. Front Oncol. 2020;9:1560. doi: 10.3389/fonc.2019.01560, PMID 32039028, PMCID PMC6985278
92. Saghiri MA, Saini RS, Heboyan A. Cytotoxicity of nanocarrier-based drug delivery in oral cancer therapy: A systematic review and meta-analysis. Cancer Control. 2025;32:1-12. doi: 10.1177/10732748241310936, PMID 39829067
93. Albano D, Argo A, Bilello G, Cumbo E, Lupatelli M, Messina P, et al. Oral squamous cell carcinoma: Features and medico-legal implications of diagnostic omission. Case Rep Dent. 2024;2024:2578271. doi: 10.1155/2024/2578271, PMID 39346800
94. Zou Z, Li B, Wen S, Lin D, Hu Q, Wang Z, et al. The current landscape of oral squamous cell carcinoma: A comprehensive analysis from ClinicalTrials.gov. Cancer Control. 2022;29:1-14. doi: 10.1177/10732748221080348
95. Chattopadhyay C, Deo V, Patel M, Chouhan C, Airun P, Jain S. Redefining Diagnostic Pathways in Oral Squamous Cell Carcinoma: Insights from a Two-Year Cohort Managed Without Biopsy. Research Square; 2025. Available from: https://www.researchsquare.com/ article/rs-7660260/v1doi:10.21203/rs.3.rs-7660260/v1 [Last accessed on 2026 Feb 14].
96. Dhilip Kumar SS, Abrahamse H. Biocompatible nanocarriers for enhanced cancer photodynamic therapy applications. Pharmaceutics. 2021;13(11):1933. doi: 10.3390/ pharmaceutics13111933, PMID 34834348
97. Ahn PH, Quon H, O’Malley BW, Weinstein G, Chalian A, Malloy K, et al. Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors. OralOncol. 2016;55:37-42. doi: 10.1016/j.oraloncology.2016.01.013, PMID 26865261, PMCID PMC4943020
98. Düzgüneş N, Piskorz J, Skupin-Mrugalska P, Yıldırım M, Sessevmez M, Cheung J. Photodynamic therapy of oral cancer and novel liposomal photosensitizers. Oral. 2023;3(3):276-94. doi: 10.3390/oral3030023
99. Allison RR. Photodynamic therapy: Oncologic horizons. Future Oncol. 2014;10(1):123-4. doi: 10.2217/fon.13.176, PMID 24328413
100. Niu Q, Sun Q, Bai R, Zhang Y, Zhuang Z, Zhang X, et al. Progress of nanomaterials-based photothermal therapy for oral squamous cell carcinoma. Int J Mol Sci. 2022;23(18):10428. doi: 10.3390/ ijms231810428, PMID 36142341
101. Špiljak B, Somogyi Škoc M, Rezić Meštrović I, Bašić K, Bando I, Šutej I. Targeting the oral mucosa: Emerging drug delivery platforms and the therapeutic potential of glycosaminoglycans. Pharmaceutics. 2025;17(9):1212. doi: 10.3390/ pharmaceutics17091212, PMID 41012547, PMCID PMC12473735
102. Okuyama K, Yanamoto S. Saliva in balancing oral and systemic health, oral cancer, and beyond: A narrative review. Cancers (Basel). 2024;16(24):4276. doi: 10.3390/cancers16244276, PMID 39766175, PMCID PMC11674559
103. Amer AA, Bingle L, Elkordy AA, Chaw CS. Overcoming oral cavity barriers for peptide delivery using advanced pharmaceutical techniques and nano-formulation platforms. Biomedicines. 2025;13(11):2735. doi: 10.3390/biomedicines13112735, PMID 41301828, PMCID PMC12650023
104. Macartney RA, Das A, Imaniyyah AG, Fricker AT, Smith AM, Fedele S, et al. In vitro and ex vivo models of the oral mucosa as platforms for the validation of novel drug delivery systems. J Tissue Eng. 2025;16:1-40. doi: 10.1177/20417314241313458, PMID 39944725, PMCID PMC11815840
105. Del Campo-Balguerías A, Lorz C, Ocaña A, Bravo I, Alonso- Moreno C. Nanotechnology-based approaches for head and neck cancer treatment. Biomed Pharmacother. 2025;193:118871. doi: 10.1016/j.biopha.2025.118871, PMID 41385861
106. Fu Y, Ge Y, Yi S, Peng Q, Jiang H, Zhou J. Smart nanoparticle delivery systems for curcumin: A targeted strategy to enhance anticancer efficacy and bioavailability. J Mater Sci Mater Med. 2026;37(1):38. doi: 10.1007/ s10856-026-07012-7, PMID 41661421, PMCID PMC12894192
107. Fan YY, Wu H, Xu C. ROS-responsive nanoplatforms for targeted tumor immunomodulation: A paradigm shift in precision cancer immunotherapy. Pharmaceutics. 2025;17(7):886. doi: 10.3390/ pharmaceutics17070886, PMID 40733095
108. Fonseca AC, Melchels FP, Ferreira MJ, Moxon SR, Potjewyd G, Dargaville TR, et al. Emulating human tissues and organs: A bioprinting perspective toward personalized medicine. Chem Rev. 2020;120(19):11128-74. doi: 10.1021/acs.chemrev.0c00342, PMID 32937071
109. Feng S, Xuan Y, Jin H, Cui M, Meng X, Liao J, et al. Nanozyme for precision treatment of hepatocellular carcinoma. Mater Today Bio. 2026;37:102840. doi: 10.1016/j.mtbio.2026.102840, PMID 41660123
110. Riera-Domingo C, Audigé A, Granja S, Cheng WC, Ho PC, Baltazar F, et al. Immunity, hypoxia, and metabolism-the Ménage à trois of cancer: Implications for immunotherapy. Physiol Rev. 2020;100(1):1-102. doi: 10.1152/physrev.00018.2019, PMID 31414610
111. Sun Q, Chen X, Luo H, Meng C, Zhu D. Cancer stem cells of head and neck squamous cell carcinoma; Distance towards clinical application; A systematic review of literature. 2023;13:4315-45.
112. Lucotti S, Kenific CM, Zhang H, Lyden D. Extracellular vesicles and particles impact the systemic landscape of cancer. EMBO J. 2022;41(18):e109288. doi: 10.15252/embj.2021109288, PMID 36052513, PMCID PMC9475536
113. Turlej E, Domaradzka A, Radzka J, Drulis-Fajdasz D, Kulbacka J, Gizak A. Cross-talk between cancer and its cellular environment-a role in cancer progression. Cells. 2025;14(6):403. doi: 10.3390/ cells14060403, PMID 40136652
114. The Shaping of Cancer by the Tumour Microenvironment and its Relevance for Cancer Therapy. MDPI; 2021. Available from: http://www.mdpi.com/books/pdfview/book/4271doi:10.3390/ books978-3-0365-1607-3 [Last accessed on 2026 Feb 14].
115. Mohan A, Narayanan S, Balasubramanian G, Sethuraman S, Krishnan UM. Dual drug loaded nanoliposomal chemotherapy: A promising strategy for treatment of head and neck squamous cell carcinoma. Eur J Pharm Biopharm. 2016;99:73-83. doi: 10.1016/j. ejpb.2015.11.017, PMID 26690333
Published
How to Cite
Issue
Section
Copyright (c) 2026 Dr Fareedi Mukram Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.